OLAPARIB AND RESVERATROL COMBINATION INDUCES ANTIPROLIFERATIVE EFFECT IN CASTRATION RESISTANT PROSTATE CANCER CELL LINE DU-145

Zeynep Didar Kayıklık; Gamze Yeşilay; Zeynep Büşra Bolat

doi:10.51477/mejs.1826974

OLAPARIB AND RESVERATROL COMBINATION INDUCES ANTIPROLIFERATIVE EFFECT IN CASTRATION RESISTANT PROSTATE CANCER CELL LINE DU-145

Abstract

Prostate cancer is aggressive when it becomes castration resistant. Current therapies include androgen deprivation, complete androgen blockade, immunotherapies, DNA repair mechanism and next generation hormonal drugs. Combinational therapies are also popular and promising for aggressive prostate tumors. Olaparib is an FDA approved drug that provides PARP inhibition in DNA damage response. Resveratrol is a natural compound that contributes to treatments for many diseases including cancers. In this study, the anti-proliferative effects of combination therapy of Olaparib and Resveratrol was investigated on castration resistant prostate cancer cell line DU-145. Anti-proliferative effect and growth inhibition of Olaparib and Resveratrol was determined by Resazurin assay and clonogenic assay, respectively. Cell cycle assay was used to determine the cell distribution. Cell death and Reactive Oxygen Species (ROS) production was determined by apoptosis and ROS assay, respectively. We observed significant decreases in the DU-145 cell population in cell viability and cell growth assays. We also examined the effects of this combination on the cell cycle and found that the combination group increased DNA content in the G2/M phase. There was no significant effect on ROS production. Finally, the Annexin V/PI assay showed cell death in combination group of DU-145 cells. Combination treatment of Olaparib and Resveratrol showed anti-proliferative and anti-cancer effect on castration resistant prostate cancer DU-145 cell line.

Keywords

Ethical Statement

The authors declare that this document requires no ethical approval.

Thanks

DU-145 cell line was a kind gift from Prof. Fikrettin Sahin lab from Yeditepe University.

References

H. Sung et al., “Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA Cancer J. Clin., vol. 71, no. 3, pp. 209–249, 2021, doi: 10.3322/caac.21660.
International Agency for Research on Cancer, “Cancer Today.” [Online]. Available: https://gco.iarc.who.int/today/. Accessed: Oct. 02, 2024.
M. B. Culp, I. Soerjomataram, J. A. Efstathiou, F. Bray, and A. Jemal, “Recent global patterns in prostate cancer incidence and mortality rates,” Eur. Urol., vol. 77, no. 1, pp. 38–52, 2020, doi: 10.1016/j.eururo.2019.08.005.
C.-T. Wu et al., “Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor,” Proc. Natl. Acad. Sci. U.S.A., vol. 104, no. 31, pp. 12679–12684, 2007, doi: 10.1073/pnas.0704940104.
D. A. Quigley et al., “Genomic hallmarks and structural variation in metastatic prostate cancer,” Cell, vol. 175, no. 3, pp. 889–908, 2018, doi: 10.1016/j.cell.2018.10.019.
D. F. Penson et al., “Enzalutamide versus bicalutamide in castration-resistant prostate cancer: The STRIVE trial,” J. Clin. Oncol., vol. 34, no. 18, pp. 2098–2106, 2016, doi: 10.1200/JCO.2015.64.9285.
M. Kirby, C. Hirst, and E. D. Crawford, “Characterising the castration-resistant prostate cancer population: A systematic review,” Int. J. Clin. Pract., vol. 65, no. 11, pp. 1180–1192, 2011, doi: 10.1111/j.1742-1241.2011.02799.x.
G. R. Cunha et al., “Development of the human prostate,” Differentiation, vol. 103, pp. 24–45, 2018, doi: 10.1016/j.diff.2018.08.005.

J. M. de Murcia et al., “Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells,” Proc. Natl. Acad. Sci. U.S.A., vol. 94, no. 14, pp. 7303–7307, 1997, doi: 10.1073/pnas.94.14.7303.
M. Shaheen, C. Allen, J. A. Nickoloff, and R. Hromas, “Synthetic lethality: Exploiting the addiction of cancer to DNA repair,” Blood, vol. 117, no. 23, pp. 6074–6082, 2011, doi: 10.1182/blood-2011-01-313734.
A. L. Heeke et al., “Prevalence of homologous recombination-related gene mutations across multiple cancer types,” JCO Precis. Oncol., vol. 2018, Art. no. PO.17.00286, 2018, doi: 10.1200/PO.17.00286.
S. Gilbert, B. Péant, A.-M. Mes-Masson, and F. Saad, “IKKε inhibitor Amlexanox promotes Olaparib sensitivity through the C/EBP-β-mediated transcription of Rad51 in castrate-resistant prostate cancer,” Cancers, vol. 14, no. 15, Art. no. 3684, 2022, doi: 10.3390/cancers14153684.
Y. Zhao, H. Tang, X. Zeng, D. Ye, and J. Liu, “Resveratrol inhibits proliferation, migration and invasion via Akt and ERK1/2 signaling pathways in renal cell carcinoma cells,” Biomed. Pharmacother., vol. 98, pp. 36–44, 2018, doi: 10.1016/j.biopha.2017.12.029.
P. Jara et al., “The effect of resveratrol on cell viability in the Burkitt’s lymphoma cell line Ramos,” Molecules, vol. 23, no. 1, Art. no. 14, 2018, doi: 10.3390/molecules23010014.
M. Elshaer, Y. Chen, X. J. Wang, and X. Tang, “Resveratrol: An overview of its anti-cancer mechanisms,” Life Sci., vol. 207, pp. 340–349, 2018, doi: 10.1016/j.lfs.2018.06.028.
Q. Ji et al., “Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression,” BMC Cancer, vol. 15, Art. no. 97, 2015, doi: 10.1186/s12885-015-1119-y.
G. A. Abdel-Latif, A. M. Al-Abd, M. G. Tadros, F. A. Al-Abbasi, A. E. Khalifa, and A. B. Abdel-Naim, “The chemomodulatory effects of resveratrol and didox on herceptin cytotoxicity in breast cancer cell lines,” Sci. Rep., vol. 5, Art. no. 12054, 2015, doi: 10.1038/srep12054.
T. Mitani, N. Harada, S. Tanimori, Y. Nakano, H. Inui, and R. Yamaji, “Resveratrol inhibits hypoxia-inducible factor-1α-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer,” J. Nutr. Sci. Vitaminol., vol. 60, no. 4, pp. 276–282, 2014.
S. Selvaraj, Y. Sun, P. Sukumaran, and B. B. Singh, “Resveratrol activates autophagic cell death in prostate cancer cells via downregulation of STIM1 and the mTOR pathway,” Mol. Carcinog., vol. 55, no. 5, pp. 818–831, 2016, doi: 10.1002/mc.22324.
O. S. Chao and O. B. Goodman, “Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP,” Mol. Cancer Res., vol. 12, no. 12, pp. 1755–1766, 2014, doi: 10.1158/1541-7786.MCR-14-0173.
C. Cattrini, M. Capaia, F. Boccardo, and P. Barboro, “Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational study,” Cancer Treat. Res. Commun., vol. 25, Art. no. 100221, 2020, doi: 10.1016/j.ctarc.2020.100221.
S. Zhou et al., “MET inhibition enhances PARP inhibitor efficacy in castration-resistant prostate cancer by suppressing the ATM/ATR and PI3K/AKT pathways,” J. Cell. Mol. Med., vol. 25, no. 24, pp. 11157–11169, 2021, doi: 10.1111/jcmm.17037.
M. K. Weil and A. P. Chen, “PARP inhibitor treatment in ovarian and breast cancer,” Curr. Probl. Cancer, vol. 35, no. 1, pp. 7–50, 2011, doi: 10.1016/j.currproblcancer.2010.12.002.
Z. Wang et al., “Targeting c-MET to enhance the efficacy of Olaparib in prostate cancer,” Onco Targets Ther., vol. 14, pp. 4383–4389, 2021, doi: 10.2147/OTT.S291267.
J. Mateo et al., “DNA-repair defects and Olaparib in metastatic prostate cancer,” N. Engl. J. Med., vol. 373, no. 18, pp. 1697–1708, 2015, doi: 10.1056/NEJMoa1506859.
M.-H. Lee, J. K. Kundu, Y.-S. Keum, Y.-Y. Cho, Y.-J. Surh, and B. Y. Choi, “Resveratrol inhibits IL-6-induced transcriptional activity of AR and STAT3 in human prostate cancer LNCaP-FGC cells,” Biomol. Ther., vol. 22, no. 5, pp. 426–430, 2014, doi: 10.4062/biomolther.2014.061.
D.-S. Han, H.-J. Lee, and E.-O. Lee, “Resveratrol suppresses serum-induced vasculogenic mimicry through impairing the EphA2/twist-VE-cadherin/AKT pathway in human prostate cancer PC-3 cells,” Sci. Rep., vol. 12, no. 1, Art. no. 20125, 2022, doi: 10.1038/s41598-022-24414-z.
Y. Wang et al., “Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines,” Hum. Mol. Genet., vol. 19, no. 22, pp. 4319–4329, 2010, doi: 10.1093/hmg/ddq354.
M. Mailland, “[Quantitative study on the effects of occlusal overload on the remodelling of the alveolar process in the rat],” J. Biol. Buccale, vol. 3, no. 4, pp. 277–288, 1975.
J. Y. Jang, E. Im, and N. D. Kim, “Mechanism of resveratrol-induced programmed cell death and new drug discovery against cancer: A review,” Int. J. Mol. Sci., vol. 23, no. 22, Art. no. 13689, 2022, doi: 10.3390/ijms232213689.
W. Xia et al., “Tumor selective G2/M cell cycle arrest and apoptosis of epithelial and hematological malignancies by BBL22, a benzazepine,” Proc. Natl. Acad. Sci. U.S.A., vol. 97, no. 13, pp. 7494–7499, 2000, doi: 10.1073/pnas.97.13.7494.
H. Wang et al., “Erianin induces G2/M-phase arrest, apoptosis, and autophagy via the ROS/JNK signaling pathway in human osteosarcoma cells in vitro and in vivo,” Cell Death Dis., vol. 7, no. 6, Art. no. e2247, 2016, doi: 10.1038/cddis.2016.138.
S. K. Singh, S. Banerjee, E. P. Acosta, J. W. Lillard, and R. Singh, “Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/p21 WAF1/CIP1 and p27 KIP1 pathway,” Oncotarget, vol. 8, no. 10, pp. 17216–17228, 2017, doi: 10.18632/oncotarget.15303.
A. Shaito et al., “Potential adverse effects of resveratrol: A literature review,” Int. J. Mol. Sci., vol. 21, no. 6, Art. no. 2084, 2020, doi: 10.3390/ijms21062084.
Á. San Hipólito-Luengo, A. Alcaide, M. Ramos-González, E. Cercas, S. Vallejo, A. Romero, E. Talero, C. F. Sánchez-Ferrer, V. Motilva, and C. Peiró, “Dual effects of resveratrol on cell death and proliferation of colon cancer cells,” Nutr. Cancer, vol. 69, no. 7, pp. 1019–1027, 2017, doi: 10.1080/01635581.2017.1359309.
B. Salehi, A. P. Mishra, M. Nigam, B. Sener, M. Kilic, M. Sharifi-Rad, P. V. T. Fokou, N. Martins, and J. Sharifi-Rad, “Resveratrol: A double-edged sword in health benefits,” Biomedicines, vol. 6, no. 3, p. 91, 2018, doi: 10.3390/biomedicines6030091.
L. Li et al., “Androgen receptor inhibitor-induced ‘BRCAness’ and PARP inhibition are synthetically lethal for castration-resistant prostate cancer,” Sci. Signal., vol. 10, no. 480, Art. no. eaam7479, 2017, doi: 10.1126/scisignal.aam7479.
S. Sinha et al., “Olaparib enhances the resveratrol-mediated apoptosis in breast cancer cells by inhibiting the homologous recombination repair pathway,” Exp. Cell Res., vol. 420, no. 1, Art. no. 113338, 2022, doi: 10.1016/j.yexcr.2022.113338.
I. Ali and D. P. Braun, “Resveratrol enhances mitomycin C-mediated suppression of human colorectal cancer cell proliferation by up-regulation of p21WAF1/CIP1,” Anticancer Res., vol. 34, no. 10, pp. 5439–5446, 2014.

Details

Primary Language

English

Subjects

Cancer Biology

Journal Section

Research Article

Authors

Zeynep Didar Kayıklık
0009-0000-9115-108X
Türkiye

Gamze Yeşilay
0000-0002-3375-8956
Türkiye

Zeynep Büşra Bolat ^*
0000-0002-9216-6336
Türkiye

Publication Date

June 29, 2026

Submission Date

November 19, 2025

Acceptance Date

June 20, 2026

Published in Issue

Year 2026 Volume: 12 Number: 1

DOI

https://doi.org/10.51477/mejs.1826974

IZ

https://izlik.org/JA84YK47TZ

Cite

RIS / Bibtex

APA

Kayıklık, Z. D., Yeşilay, G., & Bolat, Z. B. (2026). OLAPARIB AND RESVERATROL COMBINATION INDUCES ANTIPROLIFERATIVE EFFECT IN CASTRATION RESISTANT PROSTATE CANCER CELL LINE DU-145. Middle East Journal of Science, 12(1), 61-73. https://doi.org/10.51477/mejs.1826974

AMA

1.Kayıklık ZD, Yeşilay G, Bolat ZB. OLAPARIB AND RESVERATROL COMBINATION INDUCES ANTIPROLIFERATIVE EFFECT IN CASTRATION RESISTANT PROSTATE CANCER CELL LINE DU-145. MEJS. 2026;12(1):61-73. doi:10.51477/mejs.1826974

Chicago

Kayıklık, Zeynep Didar, Gamze Yeşilay, and Zeynep Büşra Bolat. 2026. “OLAPARIB AND RESVERATROL COMBINATION INDUCES ANTIPROLIFERATIVE EFFECT IN CASTRATION RESISTANT PROSTATE CANCER CELL LINE DU-145”. Middle East Journal of Science 12 (1): 61-73. https://doi.org/10.51477/mejs.1826974.

EndNote

Kayıklık ZD, Yeşilay G, Bolat ZB (June 1, 2026) OLAPARIB AND RESVERATROL COMBINATION INDUCES ANTIPROLIFERATIVE EFFECT IN CASTRATION RESISTANT PROSTATE CANCER CELL LINE DU-145. Middle East Journal of Science 12 1 61–73.

IEEE

[1]Z. D. Kayıklık, G. Yeşilay, and Z. B. Bolat, “OLAPARIB AND RESVERATROL COMBINATION INDUCES ANTIPROLIFERATIVE EFFECT IN CASTRATION RESISTANT PROSTATE CANCER CELL LINE DU-145”, MEJS, vol. 12, no. 1, pp. 61–73, June 2026, doi: 10.51477/mejs.1826974.

ISNAD

Kayıklık, Zeynep Didar - Yeşilay, Gamze - Bolat, Zeynep Büşra. “OLAPARIB AND RESVERATROL COMBINATION INDUCES ANTIPROLIFERATIVE EFFECT IN CASTRATION RESISTANT PROSTATE CANCER CELL LINE DU-145”. Middle East Journal of Science 12/1 (June 1, 2026): 61-73. https://doi.org/10.51477/mejs.1826974.

JAMA

1.Kayıklık ZD, Yeşilay G, Bolat ZB. OLAPARIB AND RESVERATROL COMBINATION INDUCES ANTIPROLIFERATIVE EFFECT IN CASTRATION RESISTANT PROSTATE CANCER CELL LINE DU-145. MEJS. 2026;12:61–73.

MLA

Kayıklık, Zeynep Didar, et al. “OLAPARIB AND RESVERATROL COMBINATION INDUCES ANTIPROLIFERATIVE EFFECT IN CASTRATION RESISTANT PROSTATE CANCER CELL LINE DU-145”. Middle East Journal of Science, vol. 12, no. 1, June 2026, pp. 61-73, doi:10.51477/mejs.1826974.

Vancouver

1.Zeynep Didar Kayıklık, Gamze Yeşilay, Zeynep Büşra Bolat. OLAPARIB AND RESVERATROL COMBINATION INDUCES ANTIPROLIFERATIVE EFFECT IN CASTRATION RESISTANT PROSTATE CANCER CELL LINE DU-145. MEJS. 2026 Jun. 1;12(1):61-73. doi:10.51477/mejs.1826974